Journal Article

Drug name headaches: a prescription for the trade mark lawyer

B. Brett Heavner

in Journal of Intellectual Property Law & Practice

Volume 2, issue 9, pages 589-592
Published in print September 2007 | ISSN: 1747-1532
Published online September 2007 | e-ISSN: 1747-1540 | DOI: http://dx.doi.org/10.1093/jiplp/jpm135
Drug name headaches: a prescription for the trade mark lawyer

More Like This

Show all results sharing these subjects:

  • Arbitration
  • Intellectual Property Law

GO

Show Summary Details

Preview

Legal context

This article highlights the difficulties in advising pharmaceutical clients on the selection and protection of trade marks given the dual trade mark approval process required by both the U.S. Patent and Trademark Office (PTO) and the U.S. Food and Drug Administration (FDA). Specifically, the article points out the inconsistencies between the different tests and procedures used by the PTO and FDA to evaluate and approve proposed pharmaceutical trade marks.

Key points

The PTO's trade mark examination focuses on (1) the inherent distinctiveness of the mark, and (2) a likelihood that the mark will be confused with a pre-existing trade mark. In contrast, the FDA's trade mark examination process focuses on (1) whether the trade mark conveys a false or confusing meaning to consumers, and (2) whether there exists another “sound alike/look-alike” pharmaceutical trade mark that could lead to prescription/dispensing errors in the marketplace. The application of the PTO and FDA examination tests and procedures often leads to different conclusions by the two agencies as to whether a particular trade mark is approved for use and registration. Moreover, the PTO and FDA each use a different method to determine which trade mark applicant has prior rights to a given trade mark. If the two agencies reach different conclusions as to which applicant has the prior rights to a given trade mark, there is no existing legal mechanism to reconcile/adjudicate these conflicting conclusions.

Practical significance

Trade mark practice in the pharmaceutical field must be adjusted to consider the FDA's specific examination tests and procedures alongside the traditional PTO analysis. Moreover, practitioners should also encourage pharmaceutical clients to submit multiple proposed trade marks for clearance and approval so that there will be multiple options should the trade mark preferred initially be rejected by either the PTO or FDA.

Keywords: The selection and subsequent registration of pharmaceutical trade marks has developed into a subgroup of trade mark practice, addressing a combination of issues that are not found elsewhere in trade mark legal practice.; Special features of this practice relate to the need to navigate a system of appellations that takes in international non-proprietary names and generic names as well as brand names, the serious and potentially fatal consequences of consumer confusion, and the interplay of bodies responsible for regulating the drugs industry, processing the grant of trade marks and the administration of justice.; This article examines the problems faced within the context of US trade mark practice, particularly from the point of the private practitioner who must advise and represent the interests of a client without necessarily having a direct input on its commercial and branding strategies.

Journal Article.  2514 words. 

Subjects: Arbitration ; Intellectual Property Law

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.